Public Comment-Hospital outpatient prospective payments for 340B
Changing the reimbursement amount for medical benefit drugs in the OPPS for hospitals in the 340B program will directly reduce the patient share (set at 20%) for those...
Changing the reimbursement amount for medical benefit drugs in the OPPS for hospitals in the 340B program will directly reduce the patient share (set at 20%) for those...
Trade associations and lobbying groups representing cancer physicians and some policymakers regularly state that oncology care costs more in the hospital outpatient department (HOPD) than in the physician...
In four recent letters to CMS, Members of Congress provided conflicting forecasts regarding how the agency’s proposed pilot program of Part B drug payment might affect many aspects...
The “buy and bill” system, the main component under scrutiny, is a reimbursement design in which physicians buy pharmaceutical drugs and submit a bill for reimbursement upon administration...
Drug prices in the United States remain the highest in the world. New payment approaches are needed, a point illustrated by the new treatments for hepatitis C virus...
Partner with Verdant for rigorous, objective economic analysis.